Skip to main content
TipRanks
Go Ultimate75% OFF

McBride (10W) Q4 2026 Earnings Report

0 Followers

DE:10W Q4 2026 EPS Results

Actual EPS
EUR 0.10
Consensus EPS
EUR 0.16
Beat/Miss
Missed by -EUR 0.06
One Year Ago EPS
EUR 0.12

DE:10W Q4 2026 Revenue Results

Actual Revenue
EUR 547.80M
Expected Revenue
EUR 546.01M
Beat/Miss
Beat by +EUR 1.79M
YoY Revenue Growth
+0.86%

Earnings Announcement Details

Quarter
Q4 2026
Date
09/15/2026
Time
Before Open
Conference Call
Tuesday, September 15, 2026
DE:10W Upcoming Earnings

McBride's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q4 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Sep 15, 2026|% Change Since:-18.57%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with management highlighting strategic execution, the completed Eurotab acquisition, the transformational Vestacy agreement, strong private label trends, transformation benefits, shareholder returns and growth in aerosols and Asia. These positives were tempered by lower constant-currency revenue and operating profit, significant fourth-quarter input-cost inflation, delayed launches, pressure in Liquids and Unit Dosing, higher expected exceptional costs and continued uncertainty surrounding the external cost environment.

Company Guidance

Management expects most delayed new product launches to start up in “this next first half year of the new financial year”; Eurotab is expected to add circa EUR 65 million of top line in “this current financial year,” while the Vestacy agreement is expected to grow revenues by an estimated GBP 170 million by the second half of financial year 2028, add some 180 million units per year and require McBride to spend approximately GBP 17 million over the next 3 years, with contract manufacturing beyond the 25% strategic ambition. The group remains committed to the 10% target for EBITDA margins and is on track for the cumulative GBP 50 million of transformation benefits by the end of FY '28; CapEx is expected to remain at current levels, the P&L finance charge is expected to increase to GBP 13 million in 2027, exceptional costs are expected to increase to some GBP 12 million in 2027, and further price rises will be required, with the oil price in the $100 to $110 range.

  • Strategic Execution and SAP ProgressManagement described the last 12 months as hugely positive, including the successful first go-live of the major SAP systems rollout and progress against the targets set at the 2024 Capital Markets Day. SAP Wave 2 is planned for go-live early in 2027.
  • Resilient Full-Year Performance Despite Q4 InflationThe group reported a resilient set of financial results in difficult and uncertain trading conditions. Excluding the GBP 6 million estimated impact of the Middle East crisis, adjusted operating profit would have been approximately GBP 65 million versus the reported GBP 59 million.
  • Private Label Market Share Reached a Record HighPrivate label share in household products increased by 1 percentage point to 36.7% by volume for the 12 months to June 2026. Over the last three years, the total market grew approximately 3.3%, while brands were flat and private label drove all market growth, increasing its share by 2.5 percentage points.
  • Eurotab Acquisition CompletedMcBride completed the acquisition of Eurotab on 1 July. Eurotab has three manufacturing locations in France and Turkey and is expected to add circa EUR 65 million of top-line revenue in the current financial year. Net consideration was EUR 32.8 million, with an acquisition multiple of 4.6x forecast to fall to 3.1x post synergies. Management expects the acquisition to be accretive to earnings per share and profitability from day 1.
  • Eurotab Expands Product and Geographic ReachEurotab adds auto-dishwash tablet capacity, particularly in the all-in-one category, as well as disinfection tablets and humidity absorption blocks. It also extends McBride's reach into Turkey and provides opportunities for raw-material buying, production efficiencies, automation, overhead simplification and cross-selling.
  • Transformative Vestacy Contract Manufacturing AgreementThe 5- to 8-year Vestacy agreement is expected to increase McBride's revenues by an estimated GBP 170 million by the second half of financial year 2028 and add approximately 180 million units per year. It is expected to take contract manufacturing beyond the 25% strategic ambition set at the 2024 Capital Markets Day.
  • Vestacy Funding and Manufacturing Footprint ExpansionThe majority of the significant capital expenditure required for the Vestacy volumes will be funded by Vestacy. McBride expects to spend approximately GBP 17 million over three years on project costs, separation, integration and limited capital, while acquiring two former Reckitt/Vestacy factories in Spain and Portugal for nominal consideration. Vestacy will fund GBP 34 million of equipment that McBride will own.
  • Progress on Transformation BenefitsThe transformation program delivered more than GBP 10 million of additional benefits during the year and GBP 15.3 million cumulatively. McBride remains on target for GBP 50 million of net benefits by financial year 2028. Commercial excellence contributed an estimated GBP 3.8 million of net benefit in 2026, while productivity excellence delivered GBP 6.5 million and OEE efficiencies improved by slightly more than 2%.
  • Capital Returns and Share Price PerformanceMcBride allocated GBP 18 million to shareholders through dividends, share buybacks and share purchases to prevent future dilution, an increase of GBP 15.6 million year-on-year. The Board recommended a 3.1p per share dividend for financial year 2026, compared with the 3p per share dividend paid for the prior year. Management also noted that the share price had risen by more than 60% since the same time last year.
  • Aerosols Delivered Strong GrowthThe aerosols business reported private label volume growth of 13% and contract manufacturing volume growth of just over 10%. Annual volumes exceeded the 100 million cans target, run rates in the early part of the new year were also above 100 million cans, and volumes were approximately 50% above the level three years earlier.
  • Liquids Safety and Vestacy Growth OpportunityThe Liquids division reported accident levels more than 50% lower in its factories. The Vestacy agreement is expected to benefit the division primarily, with approximately 90% of awarded volumes in liquid formats and more than EUR 40 million of capacity investment scheduled across its plants over the next two years.
  • Unit Dosing and Powders Operational ProgressUnit Dosing profitability improved year-over-year due to cost discipline, better factory performance and improved mix. Its new soft pod for auto dish launched well, and capacity investment continued. The Powders division recorded good volume growth, primarily in the second half, supported by new business wins and strong run-rate volumes, especially in Germany.
  • Asia Growth PlatformThe Asia business delivered good top-line growth in value terms. Although reported volume was lower due mainly to a distorting volume measure in Vietnam, underlying growth was closer to 5%, driven by strong Australia performance, the launch of household ranges manufactured in Malaysia and stronger demand from Malaysian customers.
  • Balance Sheet and Liquidity PositionManagement said debt levels were in good shape after GBP 18 million of shareholder returns. Liquidity remained healthy at GBP 167.6 million, the revolving credit facility was extended to November 2029 with a further extension to November 2030 expected, and the IAS 19 pension deficit decreased to GBP 18.1 million from GBP 23 million.
  • Early New-Year Trading In Line with ExpectationsThe first two months of the new financial year saw volumes in line with expectations. Management also identified possible early signs of additional private label demand from retailers in certain markets amid continued consumer inflation pressure.

DE:10W Earnings History

DE:10W earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272027 (Q2)―-0.13――
Sep 15, 20262026 (Q4)0.160.100.12-13.40% (-0.02)
Feb 24, 20262026 (Q2)0.100.130.14-7.89% (-0.01)
Sep 17, 20252025 (Q4)―0.120.14-19.17% (-0.03)
Feb 25, 20252025 (Q2)―0.140.1125.27% (+0.03)
Sep 17, 20242024 (Q4)―0.14-0.03600.00% (+0.17)
Feb 27, 20242024 (Q2)―0.11-0.05316.67% (+0.16)
Sep 19, 20232023 (Q4)―-0.03-0.0759.32% (+0.04)
Feb 28, 20232023 (Q2)―-0.05-0.148.15% (+0.05)
Sep 29, 20222022 (Q4)―-0.070.03-345.83% (-0.10)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed